

30 July 2026

ASX Announcement

June 2026 Quarterly Activities Report

- **GMP manufacturing of Galidesivir underway to support pivotal Marburg studies under US FDA's Animal Rule pathway and other biodefence opportunities**
- **Expanded Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Geneva Foundation**
- **USAMRIID CRADA amendment confirms planned Galidesivir dose optimisation study, which is expected to commence this quarter with topline results in Q4 CY26**
- **US FDA grants Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease**
- **Uganda Government and regulatory approvals secured for the use of Galidesivir as a treatment for infected patients during the Bundibugyo Ebola outbreak**
- **Provides opportunity to generate human data in an active outbreak setting under the World Health Organization's (WHO) internationally recognised emergency clinical framework as part of development**
- **Statement of Work executed with Texas Biomed to enhance Galidesivir dose optimisation initiatives prior to planned pivotal FDA Animal Rule efficacy study**
- **Combined studies to generate data from 32 NHPs for future FDA submission, materially strengthening dose selection, pivotal study design and overall Animal Rule regulatory package**
- **Singapore patent granted covering use of ISLA-101 to treat flavivirus, including Dengue, and Chikungunya virus infections**

MELBOURNE Australia, 30 July 2026: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to provide the following summary of activities undertaken during the three-month period ended 30 June 2026 (**quarter**).

During the period, Island delivered substantial progress across its Galidesivir program, advancing multiple regulatory, manufacturing and operational initiatives that further de-risk its FDA Animal Rule development pathway for Marburg Virus Disease. Key achievements included commencement of GMP manufacturing, execution of an expanded Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID), receipt of US FDA Orphan Drug Designation for post-exposure prophylaxis of Marburg and continued expansion of the Company's strategic engagement across the global biodefence ecosystem.

Subsequent to the end of the quarter, Island further strengthened the program through regulatory approvals enabling compassionate use of Galidesivir during the ongoing Bundibugyo Ebola outbreak in Uganda, execution of a complementary dose optimisation study with Texas Biomedical Research Institute (Texas Biomed) and expansion of its intellectual property portfolio through the grant of a Singapore patent covering ISLA-101.

Management commentary:

Chief Executive Officer and Managing Director, Dr David Foster, said: *"The June quarter represents another transformational period as we continued to systematically execute on the strategy that we established following the FDA's alignment on Galidesivir's Animal Rule development pathway earlier this year.*

"Importantly, our focus for the quarter extended well beyond simply progressing the next study. We have continued building the complete clinical, regulatory, manufacturing and commercial framework required to maximise Galidesivir's long-term value as a medical countermeasure for high-consequence viral threats.

"The commencement of GMP manufacturing, execution of our expanded CRADA with USAMRIID and receipt of FDA Orphan Drug Designation each represent important milestones that materially strengthen the foundations of the program while continuing to de-risk the pathway towards potential approval and commercialisation.

"Subsequent to the quarter, we were particularly pleased to secure all regulatory and ethics approvals required to deploy Galidesivir under the World Health Organization's MEURI framework during the ongoing Bundibugyo Ebola outbreak in Uganda. This represents a rare opportunity to generate prospective human clinical, safety and virological data during an active outbreak while simultaneously providing access to a potential treatment where no approved therapies currently exist.

"Equally significant was the execution of our agreement with Texas Biomed, which complements our ongoing USAMRIID program and expands our FDA-directed dose optimisation strategy. Together, these studies are expected to generate data from 32 non-human primates across multiple treatment windows, materially strengthening dose selection, optimising pivotal study design and further de-risking the overall Animal Rule regulatory package.

"Collectively, these initiatives demonstrate the significant momentum that has been established across the Galidesivir program. We have continued to strengthen relationships with leading biodefence institutions, government agencies and global infectious disease organisations while positioning Island at the forefront of efforts to develop a broad-spectrum antiviral capable of addressing some of the world's most significant viral threats.

"Looking ahead, we remain focused on executing the next phase of our development strategy, including progressing both FDA-directed dosing studies, preparing for the commencement of the Uganda MEURI program and continuing to advance discussions with government and biodefence stakeholders. With regulatory alignment established, manufacturing underway and multiple complementary development pathways now progressing in parallel, we believe Island has established a highly differentiated platform capable of delivering significant long-term value for shareholders."

Operational overview:

Galidesivir GMP manufacturing underway to support study and biodefence initiatives:

Island commenced Good Manufacturing Practice (GMP) manufacturing of Galidesivir, representing an important milestone in the program's transition towards late-stage development and commercial readiness.



The manufacturing campaign, being undertaken by global contract research, development and manufacturing organisation PI Health Sciences (PIHS), includes analytical method validation, reference standard preparation, stability studies and manufacture of GMP-grade Galidesivir to support the Company's planned pivotal Animal Rule efficacy study.

Importantly, Island's existing Galidesivir inventory remains available for the Company's FDA-directed dose optimisation studies, allowing pivotal study manufacturing activities to progress in parallel without impacting planned study timelines.

More broadly, the initiative establishes the manufacturing, analytical and quality systems required for future regulatory submissions, government procurement opportunities and potential biodefence stockpiling initiatives. The availability of GMP-grade material also provides strategic flexibility to respond to emerging infectious disease outbreaks and other global health security opportunities.

Expanded CRADA with USAMRIID for FDA-directed dose optimisation study:

Island further strengthened its strategic collaboration with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) through execution of an expanded Cooperative Research and Development Agreement (CRADA), resolving the final study design and operational requirements for the Company's first FDA-directed dose optimisation study.

USAMRIID is the US Army's premier biodefence research institute and one of the world's leading organisations for evaluating medical countermeasures against highly pathogenic infectious diseases under Biosafety Level 4 (BSL-4) containment.

The expanded agreement confirmed the study design required to identify the minimally effective Galidesivir dose against the FDA-preferred Angola strain of Marburg virus. The study will evaluate multiple dose regimens and treatment initiation timepoints commencing 24 to 48 hours following infection, generating the translational pharmacokinetic, efficacy and survival data required to optimise the Company's subsequent pivotal Animal Rule efficacy study.

The CRADA provides Island with access to world-leading infectious disease expertise, specialised BSL-4 infrastructure and a globally recognised biodefence institution that has played a central role in Galidesivir's historical development.

Galidesivir granted FDA Orphan Drug Designation for Marburg:

Island achieved another pleasing regulatory milestone during the period, following the FDA's grant of Orphan Drug Designation (ODD) to Galidesivir for the post-exposure prophylaxis of Marburg virus.

The designation strengthens the regulatory and commercial positioning of the Galidesivir program and provides access to a range of potential development and commercial benefits, including eligibility for seven years of market exclusivity in the US upon approval, exemption from certain FDA fees and ongoing regulatory assistance throughout development.



Government approvals secured to evaluate Galidesivir during active Ebola outbreak:

Post quarter end, Island secured all regulatory, ethics and government approvals required to enable the compassionate use of Galidesivir during the ongoing Bundibugyo Ebola outbreak in Uganda under the World Health Organization's (WHO) internationally recognised Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework.

The program is sponsored by the Uganda Ministry of Health and supported by the WHO, the ACCEPT-Africa Consortium and the Infectious Diseases Institute at Makerere University.

Importantly, the initiative provides a rare opportunity to generate prospective human clinical, safety and virological data during an active Ebola outbreak while providing eligible patients with access to a potential treatment where no approved therapeutic options currently exist.

The government-sponsored initiative is fully funded by participating institutions, with Island's contribution limited to the supply of GMP-grade Galidesivir, representing a highly capital-efficient and non-dilutive clinical development opportunity.

The MEURI program complements the Company's FDA Animal Rule strategy by establishing a second, parallel development pathway capable of generating prospective human clinical data while Animal Rule efficacy studies continue to progress.

Combined with previously generated non-human primate efficacy data demonstrating complete survival in Ebola-infected animals treated with Galidesivir, the program further strengthens the Company's long-term regulatory and commercial positioning while supporting potential future government procurement and biodefence stockpiling opportunities.

Texas Biomed agreement further de-risks pivotal Animal Rule program:

Subsequent to the end of the period, Island executed a Statement of Work with the Texas Biomedical Research Institute (Texas Biomed), establishing the second phase of the Company's FDA-directed dose optimisation program for Galidesivir.

Texas Biomed is one of only four Biosafety Level 4 facilities in the US capable of conducting non-human primate infectious disease studies and is the only privately operated BSL-4 laboratory.

The study has been specifically designed to complement the USAMRIID program by evaluating Galidesivir when treatment commences at timepoints corresponding with the onset of clinical disease, typically three to five days following infection. Whereas, the USAMRIID study is evaluating treatment commencing 24 to 48 hours following infection.

Together, the complementary studies are expected to generate pharmacokinetic, efficacy and treatment timing data across multiple therapeutic windows, identifying the minimally effective dose, optimising pivotal study design and materially strengthening the regulatory package for future FDA discussions.



Under the agreement, Texas Biomed will evaluate Galidesivir in 12 non-human primates infected with Angola strain of Marburg, with study preparation expected to commence in Q4 CY2026 ahead of infection studies in early CY2027.

Importantly, Island also secured access to an additional cohort of animals should further optimisation work be required, providing operational flexibility while maintaining development momentum.

Upon completion, the combined USAMRIID and Texas Biomed programs are expected to generate data from 32 non-human primates, representing one of the most comprehensive dose optimisation datasets assembled for Galidesivir. Collectively, these studies are expected to materially de-risk the Company's pivotal Animal Rule efficacy study while further strengthening the overall regulatory package supporting potential FDA approval and future biodefence procurement opportunities.

Asia Dengue Summit presentation highlights ISLA-101 opportunity:

During the quarter, Island presented new analysis from its completed Phase 2a PROTECT clinical study at the 9th Asia Dengue Summit in Singapore.

The presentation highlighted ISLA-101's favourable safety profile, encouraging clinical data generated through the PROTECT study and the broader commercial opportunity for antiviral therapies targeting Dengue and other mosquito-borne viral diseases.

Management also outlined the Company's dual development strategy across ISLA-101 and Galidesivir, emphasising multiple near-term clinical, regulatory and commercial catalysts across both programs.

Participation in the Asia Dengue Summit further increased awareness of Island's Dengue program among leading infectious disease clinicians, researchers and industry participants within one of the world's highest-prevalence regions for mosquito-borne viral disease.

Singapore patent strengthens ISLA-101 intellectual property portfolio:

Post period end, Island further strengthened its IP portfolio following the grant of a Singapore patent covering the use of ISLA-101 as a standalone antiviral therapy for flavivirus infections, including Dengue, together with Chikungunya virus infection.

The patent broadens protection for ISLA-101 beyond Dengue, expands the Company's commercial exclusivity across an important Asia-Pacific jurisdiction and remains in force until April 2034.

Singapore represents a strategically important market where Dengue and other mosquito-borne viral diseases remain endemic, with the patent further strengthening Island's long-term partnering and commercialisation strategy across Asia.

Corporate overview:

Strengthened scientific and biodefence expertise:

During the quarter, Island continued to strengthen its leadership and advisory capabilities through the appointment of highly experienced executives with extensive expertise in antiviral drug development, biodefence, regulatory strategy and government procurement. Notably, Island has established a Fellows Program under which they are engaging a range of key opinion leaders and experts in a more formal



and active role. Coincident with this, Island has determined that the Fellows Program effectively replaces the Scientific Advisory Board (SAB).

In May, the Company appointed former BioCryst Pharmaceuticals executive Mr Raymond Taylor as Senior Scientific Fellow. Mr Taylor brings over 40 years' experience in antiviral drug development, including 19 years at BioCryst where Galidesivir was originally developed. His experience spans clinical development, regulatory strategy and medical countermeasure programs, together with a proven track record of securing and managing more than US\$490m in US Government biodefence funding, including Strategic National Stockpile procurement contracts.

Island appointed internationally recognised infectious diseases physician, virologist and vaccinologist Professor Stephen Thomas, MD as Senior Clinical Fellow. Professor Thomas is a globally respected expert in dengue and emerging infectious diseases and brings extensive experience across vaccine development, clinical research and infectious disease preparedness. He served as Lead Principal Investigator for the global Phase III Pfizer/BioNTech COVID-19 vaccine trial and currently serves as Chief of the Division of Infectious Diseases and Director of the Institute for Global Health and Translational Science at SUNY Upstate Medical University. Professor Thomas previously spent 20 years in the US Army Medical Corps, including at the Walter Reed Army Institute of Research.

Earlier in the quarter, Island also appointed Mr Mark Herzog as Senior Global Health Security Advisor. Mr Herzog has over 25 years' experience across biodefence, government contracting and medical countermeasure initiatives, having held senior roles supporting US Department of Defense, BARDA and other government biodefence programs.

Together, these appointments significantly enhance the Company's scientific, regulatory and commercial capabilities while further strengthening Island's strategic positioning within the rapidly expanding global biodefence sector. For an updated roster of the Island Team, please see the Team page on our recently launched website at www.islandpharmaceuticals.com.

The Company also advises that, effective today, Dr Amy Patick has ceased to be a member of the Scientific Advisory Board. The Company thanks Dr Patick for her ongoing support and contributions.

Launch of new ISLA-6181 program:

The Company also advises it has designated a new program to its pipeline, broadening the Galidesivir development opportunity. The new program is focused on the development of ISLA-6181, a pre-clinical small molecule antiviral molecule that was included in the BioCryst Galidesivir program acquisition. BCX-6181 is an oral prodrug of Galidesivir. Following ingestion, the prodrug is rapidly converted into Galidesivir where the bioactivity is anticipated to be the same as Galidesivir.

Given the known safety and activity of Galidesivir, management is confident that pursuing BCX-6181 is a low-risk opportunity to advance an oral antiviral to address life threatening viruses, such as Ebola and Marburg. Planning for IND enabling studies is currently underway.



Ongoing investor engagement:

Island continued to actively engage with shareholders, institutional investors and the broader investment community through a series of presentations and webinars highlighting the Company's progress.

Management presented at the Gold Coast Investment Showcase and the Asia Dengue Summit, providing updates on the Galidesivir Animal Rule program, ISLA-101's clinical development and the Company's expanding strategic opportunities across biodefence and infectious diseases.

The Company also hosted investor webinars following major regulatory and operational milestones throughout the quarter, providing shareholders with detailed updates on the expanded USAMRIID collaboration, the FDA Animal Rule pathway and broader commercial opportunities associated with Galidesivir.

Financial summary:

The Company held cash and cash equivalents of \$12.87m at 30 June 2026 (31 March 2026: \$14.18m). Net cash used in operating activities totalled \$1.53m, which included costs related to the ongoing research and development of Galidesivir and ISLA-101, as well as staff, administration and corporate costs partially offset with receipt of the 2025FY R&D tax incentive refund of \$143k. In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in items 6.1 of the Appendix 4C were \$139,000, which includes salary for the CEO/Managing Director and Director fees (including superannuation) for the Non-Executive Chair and Non-Executive director and their consulting fees as announced to the ASX.

CEO remuneration and proposed director options

The Board approved an increase in the CEO and Managing Director's remuneration to AUD \$400,000 per annum, inclusive of health insurance effective 1 July 2026.

The Board also intends to seek shareholder approval at the upcoming AGM to issue options to directors on the following terms to each Director (Jason Carroll, Christopher Ntoumenopoulos and David Foster).

- 3,000,000 options to each Director
- Vesting:
 - 50% on FDA approval of Galidesivir in any indication
 - 50% on receipt of a US government stockpile contract
- Exercise price \$0.55 (representing approximate 19.6% premium to 20 day VWAP)
- Term: 5 years

Further information regarding the proposed issue of Director options including the detailed terms will be set out in the Company's notice of annual general meeting, which will be provided to shareholders in due course.

- Ends -

Approved for release to the ASX by the Board.



David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

ISLAND PHARMACEUTICALS LIMITED

ABN

48 641 183 842

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for	-	-
(a) research and development	(1,201)	(2,846)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(78)	(369)
(f) administration and corporate costs	(495)	(2,036)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	105	276
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	143	143
1.8 Other (provide details if material)		-
1.9 Net cash from / (used in) operating activities	(1,526)	(4,832)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	(845)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:	-	-
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	(845)
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	9,102
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	70	2,588
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(585)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	70	11,105
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	14,180	7,252
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,526)	(4,832)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(845)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	70	11,105
4.5	Effect of movement in exchange rates on cash held	147	191
4.6	Cash and cash equivalents at end of period	12,871	12,871

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	6,855	2,509
5.2	Call deposits	6,016	11,671
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	12,871	14,180

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$A'000**

139

-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

The amount at 6.1 includes salary for the CEO/Managing Director and Director fees (including superannuation) for the Non-Executive Chair and Non-Executive directors and their consulting fees, where applicable.

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

7.1 Loan facilities

7.2 Credit standby arrangements

7.3 Other (please specify)

7.4 **Total financing facilities**

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
-	-
-	-
-	-
-	-

7.5 **Unused financing facilities available at quarter end**

-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

--

8. Estimated cash available for future operating activities**\$A'000**

8.1 Net cash from / (used in) operating activities (Item 1.9)

(1,526)

8.2 Cash and cash equivalents at quarter end (Item 4.6)

12,871

8.3 Unused finance facilities available at quarter end (Item 7.5)

-

8.4 Total available funding (Item 8.2 + Item 8.3)

12,871

8.5 **Estimated quarters of funding available (Item 8.4 divided by Item 8.1)****8.4**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 July 2026
.....

Authorised by: The Board
.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.